1. Billings R. E. and Milton, S. G., Conversion of phenytoin to reactive metabolites in rat liver microsomes.Adv. Exp. Med. Biol., 197, 931–939 (1986).
2. Brofuehrer J. I., Chapman D. E., Wilke T. J. and Powis G., Comparative studies on the in vitro metabolism and covalent binding of14C-benzene by liver slices and microsomal fraction of mouse, rat and human.Drug Metab. Dispo., 18, 20–27 (1990).
3. Jollow, D. J., Mitchell, J. R., Potter, W. Z., davis, D. C., Gillette, J. R. and Brodie, B. B. Actamonophen-induced hepatic necrosis II. Role of covalent bindingin vivo.J. Pharmacol. Exp. Ther., 187, 195–212 (1973).
4. Kubow S. and Wells P. G.,In vitro bioactivation of phenytoin to a reactive free radical intermediate by prostaglandin synthethase, horseradish peroxidase, and thyroid peroxidase.Mol. Pharmacol., 35, 504–511 (1989).
5. Lee, K., Vandenberghe, Y., Herin, M., Cavalier, R., BECK, D., Li, A., Verbeke, N., Lesne, M and Roba, J., Comparative metabolism of SC-42867 and SC-51089, two PGE2 antagonist, in rat and human hepatocyte culture.Xenobiotica, 24, 25–36 (1994).